Benchmark International


In the biggest deal of the company’s 120-year history, medical device giant Becton, Dickinson & Company has announced its acquisition of C.R. Bard for $24 billion. The cash and stock deal will see Bard shareholders receive $222.93 in cash and 0.5077 shares of Becton Dickinson stock per Bard share, or $317 per Bard share based on Becton Dickinson’s closing price of $185.29. The acquisition means Becton Dickinson’s portfolio, currently comprising syringes and… Read More

%d bloggers like this: